Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/105799
DC FieldValueLanguage
dc.contributor.authorSouto, Eliana B.-
dc.contributor.authorCampos, Joana R.-
dc.contributor.authorAna, Raquel da-
dc.contributor.authorFangueiro, Joana F.-
dc.contributor.authorMartins-Gomes, Carlos-
dc.contributor.authorDurazzo, Alessandra-
dc.contributor.authorLucarini, Massimo-
dc.contributor.authorSánchez López, Elena-
dc.contributor.authorEspina, Marta-
dc.contributor.authorGarcía, Maria Luisa-
dc.contributor.authorSilva, Amélia M.-
dc.contributor.authorMendonça, Fernando-
dc.contributor.authorSantini, Antonello-
dc.contributor.authorSouto, Selma B.-
dc.date.accessioned2023-03-08T10:03:24Z-
dc.date.available2023-03-08T10:03:24Z-
dc.date.issued2020-
dc.identifier.issn2076-3417pt
dc.identifier.urihttps://hdl.handle.net/10316/105799-
dc.description.abstractDiabetic retinopathy causes vascular damage to retinal neurons, presenting characteristics of chronic inflammation. The development of new therapies capable of combating vision loss involves knowledge of inflammatory retinal changes. Studies in animal models and patients with diabetes have shown a high expression of the inflammatory molecules that are involved in the progression of diabetic retinopathy. Uveal melanoma is an eye tumour that remains highly deadly, because despite the correct treatment, it still causes metastasis in about 50% of patients. This type of tumour has the ability to produce and store melanin, which may result in resistance to therapy. Over time there has been development of new therapies for this disease, such as radiotherapy and surgical resection. In this review, we discuss diabetic retinopathy and ocular melanoma, their relationship with angiogenesis and the current anti-angiogenic therapies for their treatment.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationM-ERA-NET/0004/2015-PAIREDpt
dc.relationUIDB/04469/2020 (strategic fund)pt
dc.relationUID/AGR/04033/2019 (CITAB)pt
dc.relationresearch project: Nutraceutica come supporto nutrizionale nel paziente oncologico, CUP: B83D18000140007pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectangiogenesispt
dc.subjectvascular endothelial growth factorpt
dc.subjectinflammationpt
dc.subjectdiabetic retinopathypt
dc.subjectuveal melanomapt
dc.subjectanti-angiogenic therapypt
dc.titleDiabetic Retinopathy and Ocular Melanoma: How Far We Are?pt
dc.typearticle-
degois.publication.firstPage2777pt
degois.publication.issue8pt
degois.publication.titleApplied Sciences (Switzerland)pt
dc.peerreviewedyespt
dc.identifier.doi10.3390/app10082777pt
degois.publication.volume10pt
dc.date.embargo2020-01-01*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.orcid0000-0002-9737-6017-
Appears in Collections:FFUC- Artigos em Revistas Internacionais
Files in This Item:
Show simple item record

Page view(s)

48
checked on May 7, 2024

Download(s)

32
checked on May 7, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons